Latest Insider Transactions at Becton Dickinson & CO (BDX)
This section provides a real-time view of insider transactions for Becton Dickinson & CO (BDX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of BECTON DICKINSON & CO to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of BECTON DICKINSON & CO's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 19
2024
|
Michael David Garrison EVP & President, Medical |
SELL
Open market or private sale
|
Direct |
2,838
-31.61%
|
$632,874
$223.33 P/Share
|
|
Dec 09
2024
|
Roland Goette EVP and President, EMEA |
SELL
Open market or private sale
|
Direct |
638
-4.29%
|
$139,722
$219.03 P/Share
|
|
Dec 06
2024
|
Roland Goette EVP and President, EMEA |
SELL
Sale (or disposition) back to the issuer
|
Direct |
9,490
-38.98%
|
$2,097,290
$221.01 P/Share
|
|
Dec 06
2024
|
Roland Goette EVP and President, EMEA |
SELL
Open market or private sale
|
Direct |
4,483
-15.55%
|
$990,743
$221.01 P/Share
|
|
Dec 06
2024
|
Roland Goette EVP and President, EMEA |
BUY
Exercise of conversion of derivative security
|
Direct |
13,334
+20.88%
|
$2,093,438
$157.79 P/Share
|
|
Dec 06
2024
|
Shana Carol Neal EVP and Chief People Officer |
SELL
Open market or private sale
|
Direct |
1,000
-5.56%
|
$220,000
$220.49 P/Share
|
|
Dec 05
2024
|
David Shan EVP and Chief ISC Officer |
SELL
Open market or private sale
|
Direct |
1,500
-19.27%
|
$330,000
$220.25 P/Share
|
|
Nov 26
2024
|
Pavan Kumar Mocherla EVP & President Greater Asia |
SELL
Payment of exercise price or tax liability
|
Direct |
20
-0.7%
|
-
|
|
Nov 26
2024
|
Pavan Kumar Mocherla EVP & President Greater Asia |
BUY
Grant, award, or other acquisition
|
Direct |
1,055
+15.21%
|
-
|
|
Nov 26
2024
|
Michelle Quinn EVP and General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
376
-5.15%
|
-
|
|
Nov 26
2024
|
Michelle Quinn EVP and General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
2,348
+13.65%
|
-
|
|
Nov 26
2024
|
Shana Carol Neal EVP and Chief People Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
509
-2.75%
|
-
|
|
Nov 26
2024
|
Shana Carol Neal EVP and Chief People Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,109
+10.23%
|
-
|
|
Nov 26
2024
|
Michael Feld EVP & President, Life Sciences |
BUY
Grant, award, or other acquisition
|
Direct |
2,553
+21.74%
|
-
|
|
Nov 26
2024
|
Antoine C Ezell EVP, President Americas & CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,357
-10.18%
|
-
|
|
Nov 26
2024
|
Antoine C Ezell EVP, President Americas & CMO |
BUY
Grant, award, or other acquisition
|
Direct |
4,007
+13.95%
|
-
|
|
Nov 26
2024
|
Christopher Del Orefice EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,192
-19.45%
|
-
|
|
Nov 26
2024
|
Christopher Del Orefice EVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,899
+23.45%
|
-
|
|
Nov 26
2024
|
Richard Byrd EVP & President Interventional |
SELL
Payment of exercise price or tax liability
|
Direct |
1,204
-11.41%
|
-
|
|
Nov 26
2024
|
Richard Byrd EVP & President Interventional |
BUY
Grant, award, or other acquisition
|
Direct |
4,495
+19.44%
|
-
|
|
Nov 26
2024
|
Thomas E Polen Jr Chairman, CEO and President |
SELL
Payment of exercise price or tax liability
|
Direct |
23,564
-19.01%
|
-
|
|
Nov 26
2024
|
Thomas E Polen Jr Chairman, CEO and President |
BUY
Grant, award, or other acquisition
|
Direct |
52,124
+18.95%
|
-
|
|
Nov 26
2024
|
David Shan EVP and Chief ISC Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
124
-1.57%
|
-
|
|
Nov 26
2024
|
David Shan EVP and Chief ISC Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,216
+13.15%
|
-
|
|
Nov 26
2024
|
Roland Goette EVP and President, EMEA |
SELL
Payment of exercise price or tax liability
|
Direct |
196
-1.25%
|
-
|
|
Nov 26
2024
|
Roland Goette EVP and President, EMEA |
BUY
Grant, award, or other acquisition
|
Direct |
3,105
+9.31%
|
-
|
|
Nov 26
2024
|
Michael David Garrison EVP & President, Medical |
SELL
Payment of exercise price or tax liability
|
Direct |
1,230
-12.05%
|
-
|
|
Nov 26
2024
|
Michael David Garrison EVP & President, Medical |
BUY
Grant, award, or other acquisition
|
Direct |
4,828
+21.28%
|
-
|
|
Sep 07
2024
|
Christopher Del Orefice EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
466
-3.51%
|
-
|
|
Sep 01
2024
|
Christopher Del Orefice EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
254
-1.88%
|
-
|
|
Sep 01
2024
|
Richard Byrd EVP & President Interventional |
SELL
Payment of exercise price or tax liability
|
Direct |
216
-3.44%
|
-
|
|
Aug 20
2024
|
Michael Feld EVP & President, Life Sciences |
BUY
Grant, award, or other acquisition
|
Direct |
6,637
+50.0%
|
-
|
|
Aug 14
2024
|
Roland Goette EVP and President, EMEA |
SELL
Sale (or disposition) back to the issuer
|
Direct |
4,018
-24.2%
|
$940,212
$234.08 P/Share
|
|
Aug 14
2024
|
Roland Goette EVP and President, EMEA |
BUY
Exercise of conversion of derivative security
|
Direct |
5,295
+24.18%
|
$698,940
$132.54 P/Share
|
|
Jul 01
2024
|
Thomas J Spoerel SVPController & Chief Acct Off |
SELL
Payment of exercise price or tax liability
|
Direct |
48
-2.43%
|
-
|
|
Jun 10
2024
|
Thomas J Spoerel SVPController & Chief Acct Off |
SELL
Open market or private sale
|
Direct |
300
-13.18%
|
$71,700
$239.31 P/Share
|
|
May 15
2024
|
Roland Goette EVP and President, EMEA |
SELL
Open market or private sale
|
Direct |
3,300
-8.16%
|
$778,800
$236.58 P/Share
|
|
May 13
2024
|
Roland Goette EVP and President, EMEA |
SELL
Open market or private sale
|
Direct |
3,300
-6.46%
|
$782,100
$237.11 P/Share
|
|
Apr 30
2024
|
Michael David Garrison EVP & President, Medical |
SELL
Open market or private sale
|
Direct |
1,715
-24.17%
|
$397,880
$232.81 P/Share
|
|
Apr 04
2024
|
Shana Carol Neal EVP and Chief People Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,921
-10.49%
|
-
|
|
Mar 14
2024
|
Thomas J Spoerel SVPController & Chief Acct Off |
SELL
Open market or private sale
|
Direct |
282
-11.02%
|
$67,116
$238.29 P/Share
|
|
Mar 01
2024
|
Thomas J Spoerel SVPController & Chief Acct Off |
SELL
Payment of exercise price or tax liability
|
Direct |
36
-1.39%
|
-
|
|
Mar 01
2024
|
Michael David Garrison EVP & President, Medical |
SELL
Payment of exercise price or tax liability
|
Direct |
178
-2.45%
|
-
|
|
Mar 01
2024
|
Antoine C Ezell EVP, President Americas & CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
282
-2.94%
|
-
|
|
Jan 23
2024
|
Timothy M Ring Director |
BUY
Grant, award, or other acquisition
|
Direct |
900
+1.56%
|
-
|
|
Jan 23
2024
|
Bertram L Scott Director |
BUY
Grant, award, or other acquisition
|
Direct |
900
+2.49%
|
-
|
|
Jan 23
2024
|
Joanne Waldstreicher Director |
BUY
Grant, award, or other acquisition
|
Direct |
900
+40.49%
|
-
|
|
Jan 23
2024
|
Claire Fraser Director |
BUY
Grant, award, or other acquisition
|
Direct |
900
+3.81%
|
-
|
|
Jan 23
2024
|
Jeffrey William Henderson Director |
BUY
Grant, award, or other acquisition
|
Direct |
900
+13.91%
|
-
|
|
Jan 23
2024
|
Christopher Ian Montague Jones Director |
BUY
Grant, award, or other acquisition
|
Direct |
900
+4.04%
|
-
|